GlassScriptPhysician profile
Benjamin D Paxton
NPI 1871021840
$7,571.38
in general payments reported to CMS, 2019-2025
21 companies · $958 in 2025
The $958 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,655 · 2020: $486 · 2021: $705 · 2022: $815 · 2023: $1,372 · 2024: $1,580 · 2025: $958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,909.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,596.56 | 2022-2025 | Infuse, Miebo, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,081.08 | 2019-2021 | |
| Alcon Vision LLC | $667.72 | 2019-2025 | Total30, Dailies Total1, Precision7 |
| Tarsus Pharmaceuticals, INC. | $615.34 | 2024-2025 | Xdemvy |
| Visioneering Technologies, INC. | $584.72 | 2024 | |
| Johnson & Johnson Vision Care, INC. | $517.58 | 2019-2025 | Acuvue |
| Coopervision INC. | $353.74 | 2019-2025 | Misight Contact Lens, Myday Contact Lens |
| Novartis Pharmaceuticals Corporation | $323.96 | 2019-2023 | |
| Shire North American Group INC | $262.48 | 2019 | |
| Biotissue Holdings INC. | $243.28 | 2023-2024 | |
| Oyster Point Pharma, INC. | $232.04 | 2022-2023 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $207.69 | 2021-2023 | Bromsite, Xelpros, Cequa |
| Harrow Eye, LLC | $193.50 | 2025 | Vevye |
| Kala Pharmaceuticals, INC. | $188.35 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $103.72 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $100.20 | 2020 | |
| Thea Pharma INC. | $97.08 | 2023 | |
| Allergan, INC. | $73.88 | 2019-2021 | |
| Glaukos Corporation | $71.62 | 2022 | |
| Mallinckrodt Hospital Products INC. | $29.40 | 2023 | Acthar |
| Abbvie INC. | $27.44 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Paxton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.